Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse

Nadira Durakovic, Vedran Radojcic, Mario Skarica, Karl B. Bezak, Jonathan Powell, Ephraim J Fuchs, Leo Luznik

Research output: Contribution to journalArticle

Abstract

Murine models of bone marrow transplantation were used to study the mechanisms governing the activation of donor lymphocyte infusions (DLIs) manifesting as lymphohematopoietic graft-versus-host (LH-GVH) and graft-versus-leukemia (GVL) reactivities. We demonstrate here that established mixed chimerism influences the potency of DLI-mediated alloreactivity only in the MHC-mismatched but not MHC-matched setting. In the MHC-matched setting, high levels (≥ 40%) of residual host chimerism correlated negatively with DLI-mediated alloreactivity irrespective of the timing of their administration, the donor's previous sensitization to host antigens, or the level of residual host APCs. In vivo administration of Toll-like receptor (TLR) ligands was required to maximize DLI-mediated LH-GVH and GVL reactivities in chimeras with low levels (≤ 15%) of residual host chimerism. In contrast, coadministration of DLI with antigen-presenting cell (APC) activators was insufficient to augment their LH-GVH response in the presence of high levels of host chimerism unless the host's T cells were transiently depleted. Together, these results show the cardinal influence of donor-host incompatibility on DLI-mediated GVH responses and suggest that in MHC-matched chimeras, the induction of optimal alloreactivity requires not only donor T cells and host APCs but also TLR ligands and in the presence of high levels of host chimerism depletion of host T cells.

Original languageEnglish (US)
Pages (from-to)4564-4574
Number of pages11
JournalBlood
Volume109
Issue number10
DOIs
StatePublished - May 15 2007

Fingerprint

Chimerism
T-cells
Lymphocytes
Homologous Transplantation
Bone Marrow Transplantation
Bone
Grafts
Chemical activation
T-Lymphocytes
Transplants
Toll-Like Receptors
Leukemia
Ligands
Antigen-Presenting Cells
Lymphocyte Activation
Antigens

ASJC Scopus subject areas

  • Hematology

Cite this

Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. / Durakovic, Nadira; Radojcic, Vedran; Skarica, Mario; Bezak, Karl B.; Powell, Jonathan; Fuchs, Ephraim J; Luznik, Leo.

In: Blood, Vol. 109, No. 10, 15.05.2007, p. 4564-4574.

Research output: Contribution to journalArticle

@article{e525d256ef1b45d0bf01e3ed6b701013,
title = "Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse",
abstract = "Murine models of bone marrow transplantation were used to study the mechanisms governing the activation of donor lymphocyte infusions (DLIs) manifesting as lymphohematopoietic graft-versus-host (LH-GVH) and graft-versus-leukemia (GVL) reactivities. We demonstrate here that established mixed chimerism influences the potency of DLI-mediated alloreactivity only in the MHC-mismatched but not MHC-matched setting. In the MHC-matched setting, high levels (≥ 40{\%}) of residual host chimerism correlated negatively with DLI-mediated alloreactivity irrespective of the timing of their administration, the donor's previous sensitization to host antigens, or the level of residual host APCs. In vivo administration of Toll-like receptor (TLR) ligands was required to maximize DLI-mediated LH-GVH and GVL reactivities in chimeras with low levels (≤ 15{\%}) of residual host chimerism. In contrast, coadministration of DLI with antigen-presenting cell (APC) activators was insufficient to augment their LH-GVH response in the presence of high levels of host chimerism unless the host's T cells were transiently depleted. Together, these results show the cardinal influence of donor-host incompatibility on DLI-mediated GVH responses and suggest that in MHC-matched chimeras, the induction of optimal alloreactivity requires not only donor T cells and host APCs but also TLR ligands and in the presence of high levels of host chimerism depletion of host T cells.",
author = "Nadira Durakovic and Vedran Radojcic and Mario Skarica and Bezak, {Karl B.} and Jonathan Powell and Fuchs, {Ephraim J} and Leo Luznik",
year = "2007",
month = "5",
day = "15",
doi = "10.1182/blood-2006-09-048124",
language = "English (US)",
volume = "109",
pages = "4564--4574",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse

AU - Durakovic, Nadira

AU - Radojcic, Vedran

AU - Skarica, Mario

AU - Bezak, Karl B.

AU - Powell, Jonathan

AU - Fuchs, Ephraim J

AU - Luznik, Leo

PY - 2007/5/15

Y1 - 2007/5/15

N2 - Murine models of bone marrow transplantation were used to study the mechanisms governing the activation of donor lymphocyte infusions (DLIs) manifesting as lymphohematopoietic graft-versus-host (LH-GVH) and graft-versus-leukemia (GVL) reactivities. We demonstrate here that established mixed chimerism influences the potency of DLI-mediated alloreactivity only in the MHC-mismatched but not MHC-matched setting. In the MHC-matched setting, high levels (≥ 40%) of residual host chimerism correlated negatively with DLI-mediated alloreactivity irrespective of the timing of their administration, the donor's previous sensitization to host antigens, or the level of residual host APCs. In vivo administration of Toll-like receptor (TLR) ligands was required to maximize DLI-mediated LH-GVH and GVL reactivities in chimeras with low levels (≤ 15%) of residual host chimerism. In contrast, coadministration of DLI with antigen-presenting cell (APC) activators was insufficient to augment their LH-GVH response in the presence of high levels of host chimerism unless the host's T cells were transiently depleted. Together, these results show the cardinal influence of donor-host incompatibility on DLI-mediated GVH responses and suggest that in MHC-matched chimeras, the induction of optimal alloreactivity requires not only donor T cells and host APCs but also TLR ligands and in the presence of high levels of host chimerism depletion of host T cells.

AB - Murine models of bone marrow transplantation were used to study the mechanisms governing the activation of donor lymphocyte infusions (DLIs) manifesting as lymphohematopoietic graft-versus-host (LH-GVH) and graft-versus-leukemia (GVL) reactivities. We demonstrate here that established mixed chimerism influences the potency of DLI-mediated alloreactivity only in the MHC-mismatched but not MHC-matched setting. In the MHC-matched setting, high levels (≥ 40%) of residual host chimerism correlated negatively with DLI-mediated alloreactivity irrespective of the timing of their administration, the donor's previous sensitization to host antigens, or the level of residual host APCs. In vivo administration of Toll-like receptor (TLR) ligands was required to maximize DLI-mediated LH-GVH and GVL reactivities in chimeras with low levels (≤ 15%) of residual host chimerism. In contrast, coadministration of DLI with antigen-presenting cell (APC) activators was insufficient to augment their LH-GVH response in the presence of high levels of host chimerism unless the host's T cells were transiently depleted. Together, these results show the cardinal influence of donor-host incompatibility on DLI-mediated GVH responses and suggest that in MHC-matched chimeras, the induction of optimal alloreactivity requires not only donor T cells and host APCs but also TLR ligands and in the presence of high levels of host chimerism depletion of host T cells.

UR - http://www.scopus.com/inward/record.url?scp=34248348329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248348329&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-09-048124

DO - 10.1182/blood-2006-09-048124

M3 - Article

C2 - 17227829

AN - SCOPUS:34248348329

VL - 109

SP - 4564

EP - 4574

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -